Advisory Services Network’s Cartesian Therapeutics RNAC Stock Holding History

Advisory Services Network’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-200	Closed	-$6.78K	–	4114
2022 Q4	$6.78K	Buy	+200	New	+$8.51K	﹤0.01%	3018
2021 Q4	–	Sell	-333	Closed	-$42K	–	1488
2021 Q3	$42K	Hold	333	–	–	﹤0.01%	1365
2021 Q2	$42K	Hold	333	–	–	﹤0.01%	2098
2021 Q1	$45K	Hold	333	–	–	﹤0.01%	1262
2020 Q4	$30K	Buy	333 +320	+2,462%	+$27.7K	﹤0.01%	1936
2020 Q3	$1K	Buy	+13	New	+$996	﹤0.01%	3389

Other funds holding RNAC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

MFS

Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Advisory Services Network's RNAC Position: Q1 2023 in Review

Advisory Services Network sold out of Cartesian Therapeutics (RNAC) in Q1 2023, closing a stake of 200 shares — an estimated $6.78K sold.

Advisory Services Network first reported a position in RNAC in Q3 2020 and held it in 6 quarters. The position peaked at $45K in Q1 2021. 93 funds tracked by Wall St. Rank hold RNAC as of Q1 2023.

Advisory Services Network reported no remaining Cartesian Therapeutics position as of Q1 2023 after selling out during the quarter.
Advisory Services Network sold 200 Cartesian Therapeutics shares in Q1 2023, an estimated $6.78K.
Advisory Services Network first reported a position in Cartesian Therapeutics in Q3 2020 and held it in 6 quarters.
Advisory Services Network's Cartesian Therapeutics position peaked at $45K in Q1 2021.
93 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2023.

Based on Advisory Services Network's 13F filing for Q1 2023, filed 17 May 2023.